

ERRATUM

Erratum to: Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting

Daniel H. Deck · Jennifer M. Jordan · Thomas L. Holland · Weihong Fan ·
Matthew A. Wikler · Katherine A. Sulham · G. Ralph Corey

Published online: August 26, 2016
© The Author(s) 2016. This article is published with open access at Springerlink.com

Erratum to: Infect Dis Ther (2016)
DOI 10.1007/s40121-016-0119-9

Following publication of the aforementioned article, the authors noted a minor error in Table 1 and two small errors in Table 2. In Table 1, the Eron Class III Clinical Criteria should read CrCl <30 mL/min or on dialysis, not CrCl <20 mL/min. In Table 2, Distribution of SOLO patients in modified Eron Classes I–III, the number of outpatients receiving vancomycin (VAN) in Class I should be 111, not 11. The total number of inpatients (Class I–III) was omitted, $n = 1143$ (59.8%).

The online version of the original article can be found under doi:[10.1007/s40121-016-0119-9](https://doi.org/10.1007/s40121-016-0119-9).

D. H. Deck (✉) · J. M. Jordan (✉) · W. Fan ·
M. A. Wikler · K. A. Sulham
The Medicines Company, Parsippany, NJ, USA
e-mail: Daniel.Deck@THEMEDCO.com

J. M. Jordan
e-mail: Jennifer.jordan@themedco.com

T. L. Holland · G. Ralph Corey
Duke University Hospital, Durham, NC, USA

Table 1 Clinical criteria used to define modified Eron Classes I–IV

Eron class	Clinical criteria
IV	Bacteremia (positive blood culture); or Absolute total neutrophils count <500
III	Meeting SIRS criteria CrCl <30 mL/min or on dialysis ALT/AST >10-times ULN Heart rate >90/min, breath rate >20/min, or systolic BP <90 mmHg; or Cancer
II	Age ≥75 years old Glucose >11.1 mmol/L Congestive heart failure at the randomization 30 mL/min < CrCl <60 mL/min Hepatitis (excluding AST/ALT >10-times ULN) Peripheral vascular disease Diabetes mellitus Fever (temperature >38.0 °C); or BMI ≥30 kg/m ²
I	For the patients who didn't meet Classes II–IV

ALT alanine transaminase, *AST* aspartate transaminase, *BMI* body mass index, *BP* blood pressure, *CrCl* creatinine clearance, *SIRS* systemic inflammatory response syndrome, *ULN* upper limit of normal

Table 2 Distribution of SOLO patients in modified Eron Classes I–III (mITT population, *n* = 1959)

	Class I	Class II	Class III	Total (Class I–III)
SOLO mITT (<i>n</i> = 1959)	520 (26.5%)	790 (40.3%)	600 (30.6%)	1910
Inpatients, <i>n</i> (%)	301 (57.9%)	431 (54.6%)	411 (68.5%)	1143 (59.8%)
ORI, <i>n</i>	144	224	203	571
VAN, <i>n</i>	157	207	208	572
Outpatients, <i>n</i> (%)	219 (42.1%)	359 (45.4%)	189 (31.5%)	767 (40.2%)
ORI, <i>n</i>	108	182	89	379
VAN, <i>n</i>	111	177	100	388

mITT modified intent-to-treat, *ORI* oritavancin, *VAN* vancomycin

Open Access. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use,

distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.